IL274299B2 - Methods, compositions and components for editing TGFBR2 by CRISPR-CAS9 in T cells for immunotherapy - Google Patents
Methods, compositions and components for editing TGFBR2 by CRISPR-CAS9 in T cells for immunotherapyInfo
- Publication number
- IL274299B2 IL274299B2 IL274299A IL27429920A IL274299B2 IL 274299 B2 IL274299 B2 IL 274299B2 IL 274299 A IL274299 A IL 274299A IL 27429920 A IL27429920 A IL 27429920A IL 274299 B2 IL274299 B2 IL 274299B2
- Authority
- IL
- Israel
- Prior art keywords
- cells
- cell
- tgfbr2
- genome editing
- editing system
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/10—Cellular immunotherapy characterised by the cell type used
- A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
- A61K40/31—Chimeric antigen receptors [CAR]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
- A61K40/41—Vertebrate antigens
- A61K40/42—Cancer antigens
- A61K40/4202—Receptors, cell surface antigens or cell surface determinants
- A61K40/4214—Receptors for cytokines
- A61K40/4215—Receptors for tumor necrosis factors [TNF], e.g. lymphotoxin receptor [LTR], CD30
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
- C12N15/102—Mutagenizing nucleic acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1138—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
- C12N9/22—Ribonucleases [RNase]; Deoxyribonucleases [DNase]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2121/00—Preparations for use in therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
- A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
- A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
- A61K2239/48—Blood cells, e.g. leukemia or lymphoma
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/7051—T-cell receptor (TcR)-CD3 complex
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/20—Type of nucleic acid involving clustered regularly interspaced short palindromic repeats [CRISPR]
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Zoology (AREA)
- General Health & Medical Sciences (AREA)
- Wood Science & Technology (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- Epidemiology (AREA)
- Medicinal Chemistry (AREA)
- Plant Pathology (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Crystallography & Structural Chemistry (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Immunology (AREA)
- Cell Biology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Hematology (AREA)
- Developmental Biology & Embryology (AREA)
- Virology (AREA)
- Enzymes And Modification Thereof (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762580320P | 2017-11-01 | 2017-11-01 | |
| PCT/US2018/058635 WO2019089884A2 (en) | 2017-11-01 | 2018-11-01 | Methods, compositions and components for crispr-cas9 editing of tgfbr2 in t cells for immunotherapy |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| IL274299A IL274299A (en) | 2020-06-30 |
| IL274299B1 IL274299B1 (en) | 2026-01-01 |
| IL274299B2 true IL274299B2 (en) | 2026-05-01 |
Family
ID=64453598
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL274299A IL274299B2 (en) | 2017-11-01 | 2018-11-01 | Methods, compositions and components for editing TGFBR2 by CRISPR-CAS9 in T cells for immunotherapy |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US12698489B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP3704251A2 (cg-RX-API-DMAC7.html) |
| JP (3) | JP7785452B2 (cg-RX-API-DMAC7.html) |
| KR (1) | KR102954207B1 (cg-RX-API-DMAC7.html) |
| CN (1) | CN111527209B (cg-RX-API-DMAC7.html) |
| AU (2) | AU2018358250B2 (cg-RX-API-DMAC7.html) |
| BR (1) | BR112020008478A2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3081456A1 (cg-RX-API-DMAC7.html) |
| IL (1) | IL274299B2 (cg-RX-API-DMAC7.html) |
| MA (1) | MA50858A (cg-RX-API-DMAC7.html) |
| MX (2) | MX2020004608A (cg-RX-API-DMAC7.html) |
| SG (1) | SG11202003862PA (cg-RX-API-DMAC7.html) |
| WO (1) | WO2019089884A2 (cg-RX-API-DMAC7.html) |
Families Citing this family (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2019165121A1 (en) | 2018-02-21 | 2019-08-29 | Board Of Regents, The University Of Texas System | Methods for activation and expansion of natural killer cells and uses therof |
| CN110904045A (zh) * | 2018-09-17 | 2020-03-24 | 中国科学院动物研究所 | 经修饰的t细胞、其制备方法及用途 |
| KR20210137085A (ko) | 2019-03-05 | 2021-11-17 | 엔카르타, 인크. | Cd19 유도된 키메라 항원 수용체 및 면역 요법에서 이의 용도 |
| CA3136737A1 (en) * | 2019-05-01 | 2020-11-05 | Juno Therapeutics, Inc. | Cells expressing a recombinant receptor from a modified tgfbr2 locus, related polynucleotides and methods |
| EP4768574A2 (en) | 2019-05-29 | 2026-07-01 | Monsanto Technology LLC | METHODS AND COMPOSITIONS FOR GENERATING DOMINANT ALLELES USING GENOME EDITING |
| US12024711B2 (en) | 2019-05-29 | 2024-07-02 | Monsanto Technology Llc | Methods and compositions for generating dominant short stature alleles using genome editing |
| CN114174325A (zh) * | 2019-06-04 | 2022-03-11 | 恩卡尔塔公司 | 用于免疫疗法的工程化自然杀伤细胞和工程化t细胞的组合 |
| EP3999527A4 (en) * | 2019-07-18 | 2024-04-17 | Memorial Sloan Kettering Cancer Center | METHODS AND COMPOSITIONS FOR TARGETING TGF-BETA SIGNALIZING IN CD4+ HELPER T CELLS FOR CANCER IMMUNOTHERAPY |
| EP4061927A4 (en) * | 2019-11-20 | 2024-11-13 | Cartherics Pty. Ltd. | METHOD FOR PROVIDING IMMUNE CELLS WITH ENHANCED FUNCTION |
| EP4076476A4 (en) * | 2019-12-17 | 2023-11-22 | The General Hospital Corporation | MODIFIED IMMUNE CELLS WITH REDUCED TOXICITY AND THEIR USES |
| CN114929250A (zh) * | 2019-12-18 | 2022-08-19 | 爱迪塔斯医药公司 | 用于疗法的经工程化的细胞 |
| US20230096378A1 (en) | 2020-03-12 | 2023-03-30 | Institute For Basic Science | Composition for inducing apoptosis of cells having genomic sequence variation and method for inducing apoptosis of cells by using composition |
| CN114164231B (zh) * | 2020-09-10 | 2024-05-17 | 上海邦耀生物科技有限公司 | 对细胞中的靶位点进行基因编辑的方法 |
| KR20230074515A (ko) * | 2020-09-23 | 2023-05-30 | 크리스퍼 테라퓨틱스 아게 | 개선된 기능성 및 지속성을 갖는 붕괴된 레그나제-1 및/또는 tgfbrii를 지니는 유전자 조작된 t 세포 |
| AU2022216614B2 (en) | 2021-02-05 | 2026-03-05 | Christiana Care Gene Editing Institute, Inc. | Methods of and compositions for reducing gene expression and/or activity |
| JP2024517641A (ja) * | 2021-04-20 | 2024-04-23 | ボード オブ リージェンツ,ザ ユニバーシティ オブ テキサス システム | 免疫細胞の遺伝子改変および治療的使用のための方法および組成物 |
| WO2023081900A1 (en) | 2021-11-08 | 2023-05-11 | Juno Therapeutics, Inc. | Engineered t cells expressing a recombinant t cell receptor (tcr) and related systems and methods |
| EP4469577A4 (en) * | 2022-01-26 | 2026-04-15 | Orthobio Therapeutics Inc | GENE EDITING TO IMPROVE JOINT FUNCTION |
| US20230331841A1 (en) * | 2022-03-23 | 2023-10-19 | Crispr Therapeutics Ag | Anti-cd83 car-t cells with regnase-1 and/or tgfbrii disruption |
| WO2024058589A1 (ko) * | 2022-09-16 | 2024-03-21 | 한국과학기술연구원 | 유전자 가위 넉-인을 이용하여 제조한 키메릭 항원 수용체 세포 및 이의 용도 |
| TW202442689A (zh) | 2023-03-03 | 2024-11-01 | 美商亞森諾生物科學公司 | 靶向psma及ca9之系統 |
| CN116515766A (zh) * | 2023-06-30 | 2023-08-01 | 上海贝斯昂科生物科技有限公司 | 一种自然杀伤细胞、其制备方法及用途 |
| WO2025038637A1 (en) * | 2023-08-14 | 2025-02-20 | Intellia Therapeutics, Inc. | Compositions and methods for genetically modifying transforming growth factor beta receptor type 2 (tgfβr2) |
| WO2025038648A1 (en) * | 2023-08-14 | 2025-02-20 | Intellia Therapeutics, Inc. | Compositions and methods for genetically modifying transforming growth factor beta receptor type 2 (tgfβr2) |
| WO2025137646A1 (en) | 2023-12-22 | 2025-06-26 | Recode Therapeutics, Inc. | Gene editing methods and compositions for treating cystic fibrosis |
| WO2025165915A1 (en) * | 2024-01-31 | 2025-08-07 | Adicet Therapeutics, Inc. | Compositions and methods for enhancing engineered t cell therapies |
| US20250345431A1 (en) | 2024-05-10 | 2025-11-13 | Juno Therapeutics, Inc. | Genetically engineered t cells expressing a cd19 chimeric antigen receptor (car) and uses thereof for allogeneic cell therapy |
| WO2026067458A1 (en) * | 2024-09-24 | 2026-04-02 | Geneditbio Limited | Methods and compositions for tgfbi gene editing and therapy using crispr system and engineered protein delivery vehicle |
| WO2026123001A2 (en) | 2024-12-06 | 2026-06-11 | Umoja Biopharma, Inc. | Lineage-loci engineered cell therapy and related methods of producing and using same |
| WO2026136848A2 (en) | 2024-12-20 | 2026-06-25 | Juno Therapeutics, Inc. | Cd70-targeted cars and engineered cells comprising same and related methods |
Family Cites Families (52)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4690915A (en) | 1985-08-08 | 1987-09-01 | The United States Of America As Represented By The Department Of Health And Human Services | Adoptive immunotherapy as a treatment modality in humans |
| IN165717B (cg-RX-API-DMAC7.html) | 1986-08-07 | 1989-12-23 | Battelle Memorial Institute | |
| US5219740A (en) | 1987-02-13 | 1993-06-15 | Fred Hutchinson Cancer Research Center | Retroviral gene transfer into diploid fibroblasts for gene therapy |
| ATE159548T1 (de) | 1990-11-13 | 1997-11-15 | Immunex Corp | Bifunktionelle wählbare fusionsgene |
| AU6953394A (en) | 1993-05-21 | 1994-12-20 | Targeted Genetics Corporation | Bifunctional selectable fusion genes based on the cytosine deaminase (cd) gene |
| US5827642A (en) | 1994-08-31 | 1998-10-27 | Fred Hutchinson Cancer Research Center | Rapid expansion method ("REM") for in vitro propagation of T lymphocytes |
| WO1996013593A2 (en) | 1994-10-26 | 1996-05-09 | Procept, Inc. | Soluble single chain t cell receptors |
| WO1996018105A1 (en) | 1994-12-06 | 1996-06-13 | The President And Fellows Of Harvard College | Single chain t-cell receptor |
| DE19608753C1 (de) | 1996-03-06 | 1997-06-26 | Medigene Gmbh | Transduktionssystem und seine Verwendung |
| US6451995B1 (en) | 1996-03-20 | 2002-09-17 | Sloan-Kettering Institute For Cancer Research | Single chain FV polynucleotide or peptide constructs of anti-ganglioside GD2 antibodies, cells expressing same and related methods |
| CA2305630C (en) | 1997-10-02 | 2012-11-06 | Sunol Molecular Corporation | Soluble single-chain t-cell receptor proteins |
| NZ507886A (en) | 1998-05-19 | 2003-05-30 | Avidex Ltd | Multivalent T cell receptor complexes |
| WO2000014257A1 (en) | 1998-09-04 | 2000-03-16 | Sloan-Kettering Institute For Cancer Research | Fusion receptors specific for prostate-specific membrane antigen and uses thereof |
| AU2472400A (en) | 1998-10-20 | 2000-05-08 | City Of Hope | CD20-specific redirected T cells and their use in cellular immunotherapy of CD20+ malignancies |
| CA2410510A1 (en) | 2000-06-02 | 2001-12-13 | Memorial Sloan-Kettering Cancer Center | Artificial antigen presenting cells and methods of use thereof |
| US7446179B2 (en) | 2000-11-07 | 2008-11-04 | City Of Hope | CD19-specific chimeric T cell receptor |
| US7070995B2 (en) | 2001-04-11 | 2006-07-04 | City Of Hope | CE7-specific redirected immune cells |
| US20090257994A1 (en) | 2001-04-30 | 2009-10-15 | City Of Hope | Chimeric immunoreceptor useful in treating human cancers |
| US20030170238A1 (en) | 2002-03-07 | 2003-09-11 | Gruenberg Micheal L. | Re-activated T-cells for adoptive immunotherapy |
| US7446190B2 (en) | 2002-05-28 | 2008-11-04 | Sloan-Kettering Institute For Cancer Research | Nucleic acids encoding chimeric T cell receptors |
| AU2003271904B2 (en) | 2002-10-09 | 2009-03-05 | Adaptimmune Limited | Single chain recombinant T cell receptors |
| EP2305813A3 (en) * | 2002-11-14 | 2012-03-28 | Dharmacon, Inc. | Fuctional and hyperfunctional sirna |
| US20050129671A1 (en) | 2003-03-11 | 2005-06-16 | City Of Hope | Mammalian antigen-presenting T cells and bi-specific T cells |
| EP1791865B1 (en) | 2004-06-29 | 2010-07-28 | Immunocore Ltd. | Cells expressing a modified t cell receptor |
| EP1809669A2 (en) | 2004-10-01 | 2007-07-25 | Avidex Ltd | T-cell receptors containing a non-native disulfide interchain bond linked to therapeutic agents |
| WO2008109546A2 (en) | 2007-03-02 | 2008-09-12 | Mdrna, Inc. | Nucleic acid compounds for inhibiting tgfbr gene expression and uses thereof |
| US8389282B2 (en) | 2007-03-30 | 2013-03-05 | Memorial Sloan-Kettering Cancer Center | Constitutive expression of costimulatory ligands on adoptively transferred T lymphocytes |
| US8479118B2 (en) | 2007-12-10 | 2013-07-02 | Microsoft Corporation | Switching search providers within a browser search box |
| JP5173594B2 (ja) | 2008-05-27 | 2013-04-03 | キヤノン株式会社 | 管理装置、画像形成装置及びそれらの処理方法 |
| WO2011044186A1 (en) | 2009-10-06 | 2011-04-14 | The Board Of Trustees Of The University Of Illinois | Human single-chain t cell receptors |
| PH12013501201A1 (en) | 2010-12-09 | 2013-07-29 | Univ Pennsylvania | Use of chimeric antigen receptor-modified t cells to treat cancer |
| WO2012129514A1 (en) | 2011-03-23 | 2012-09-27 | Fred Hutchinson Cancer Research Center | Method and compositions for cellular immunotherapy |
| US8398282B2 (en) | 2011-05-12 | 2013-03-19 | Delphi Technologies, Inc. | Vehicle front lighting assembly and systems having a variable tint electrowetting element |
| WO2013071154A1 (en) | 2011-11-11 | 2013-05-16 | Fred Hutchinson Cancer Research Center | Cyclin a1-targeted t-cell immunotherapy for cancer |
| EP2814846B1 (en) | 2012-02-13 | 2020-01-08 | Seattle Children's Hospital d/b/a Seattle Children's Research Institute | Bispecific chimeric antigen receptors and therapeutic uses thereof |
| WO2013126726A1 (en) | 2012-02-22 | 2013-08-29 | The Trustees Of The University Of Pennsylvania | Double transgenic t cells comprising a car and a tcr and their methods of use |
| NZ702108A (en) | 2012-05-03 | 2016-09-30 | Hutchinson Fred Cancer Res | Enhanced affinity t cell receptors and methods for making the same |
| LT2884999T (lt) | 2012-08-20 | 2021-04-12 | Fred Hutchinson Cancer Research Center | Ląstelinės imunoterapijos būdas ir kompozicijos |
| RU2729401C2 (ru) | 2012-10-02 | 2020-08-06 | Мемориал Слоан-Кеттеринг Кэнсер Сентер | Композиции и способы для иммунотерапии |
| WO2014055815A1 (en) | 2012-10-05 | 2014-04-10 | Cincinnati Children's Hospital Medical Center | Sebocyte cell culturing and methods of use |
| JP5372297B1 (ja) | 2012-12-20 | 2013-12-18 | 三菱電機株式会社 | 車載装置及びプログラム |
| CN105408483A (zh) * | 2013-03-15 | 2016-03-16 | 通用医疗公司 | 遗传和表观遗传调节蛋白至特定基因组基因座的rna引导的靶向 |
| WO2014204723A1 (en) | 2013-06-17 | 2014-12-24 | The Broad Institute Inc. | Oncogenic models based on delivery and use of the crispr-cas systems, vectors and compositions |
| US9108442B2 (en) | 2013-08-20 | 2015-08-18 | Ricoh Company, Ltd. | Image forming apparatus |
| WO2015048577A2 (en) | 2013-09-27 | 2015-04-02 | Editas Medicine, Inc. | Crispr-related methods and compositions |
| CN111218447B (zh) * | 2013-11-07 | 2024-10-11 | 爱迪塔斯医药有限公司 | 使用统治型gRNA的CRISPR相关方法和组合物 |
| US9938521B2 (en) | 2014-03-10 | 2018-04-10 | Editas Medicine, Inc. | CRISPR/CAS-related methods and compositions for treating leber's congenital amaurosis 10 (LCA10) |
| SG11201608701QA (en) * | 2014-04-18 | 2016-11-29 | Editas Medicine Inc | Crispr-cas-related methods, compositions and components for cancer immunotherapy |
| WO2016073990A2 (en) | 2014-11-07 | 2016-05-12 | Editas Medicine, Inc. | Methods for improving crispr/cas-mediated genome-editing |
| EP3020813A1 (en) * | 2014-11-16 | 2016-05-18 | Neurovision Pharma GmbH | Antisense-oligonucleotides as inhibitors of TGF-R signaling |
| EP4339287A3 (en) | 2015-07-31 | 2024-05-22 | Regents Of The University Of Minnesota | Modified cells and methods of therapy |
| SG10201913151TA (en) * | 2015-09-09 | 2020-03-30 | Seattle Childrens Hospital Dba Seattle Childrens Res Inst | Genetic engineering of macrophages for immunotherapy |
-
2018
- 2018-11-01 CA CA3081456A patent/CA3081456A1/en active Pending
- 2018-11-01 MA MA050858A patent/MA50858A/fr unknown
- 2018-11-01 WO PCT/US2018/058635 patent/WO2019089884A2/en not_active Ceased
- 2018-11-01 US US16/758,842 patent/US12698489B2/en active Active
- 2018-11-01 EP EP18807785.3A patent/EP3704251A2/en active Pending
- 2018-11-01 CN CN201880084188.9A patent/CN111527209B/zh active Active
- 2018-11-01 BR BR112020008478-6A patent/BR112020008478A2/pt unknown
- 2018-11-01 MX MX2020004608A patent/MX2020004608A/es unknown
- 2018-11-01 JP JP2020543733A patent/JP7785452B2/ja active Active
- 2018-11-01 KR KR1020207015701A patent/KR102954207B1/ko active Active
- 2018-11-01 AU AU2018358250A patent/AU2018358250B2/en active Active
- 2018-11-01 IL IL274299A patent/IL274299B2/en unknown
- 2018-11-01 SG SG11202003862PA patent/SG11202003862PA/en unknown
-
2020
- 2020-07-13 MX MX2025010535A patent/MX2025010535A/es unknown
-
2023
- 2023-09-11 JP JP2023146660A patent/JP2023179469A/ja active Pending
-
2025
- 2025-08-01 JP JP2025129240A patent/JP2025156493A/ja active Pending
- 2025-08-29 AU AU2025223904A patent/AU2025223904A1/en active Pending
Non-Patent Citations (1)
| Title |
|---|
| DOENCH, JOHN G., ET AL., OPTIMIZED SGRNA DESIGN TO MAXIMIZE ACTIVITY AND MINIMIZE OFF-TARGET EFFECTS OF CRISPR-CAS9., 18 January 2016 (2016-01-18) * |
Also Published As
| Publication number | Publication date |
|---|---|
| JP7785452B2 (ja) | 2025-12-15 |
| WO2019089884A3 (en) | 2019-06-13 |
| EP3704251A2 (en) | 2020-09-09 |
| CN111527209B (zh) | 2024-11-12 |
| IL274299A (en) | 2020-06-30 |
| IL274299B1 (en) | 2026-01-01 |
| KR102954207B1 (ko) | 2026-04-16 |
| US12698489B2 (en) | 2026-08-04 |
| JP2025156493A (ja) | 2025-10-14 |
| CN111527209A (zh) | 2020-08-11 |
| SG11202003862PA (en) | 2020-05-28 |
| RU2020117752A (ru) | 2021-12-01 |
| US20230061455A1 (en) | 2023-03-02 |
| KR20200075000A (ko) | 2020-06-25 |
| MA50858A (fr) | 2020-09-09 |
| JP2023179469A (ja) | 2023-12-19 |
| AU2025223904A1 (en) | 2025-09-18 |
| MX2020004608A (es) | 2020-10-05 |
| AU2018358250A1 (en) | 2020-05-14 |
| MX2025010535A (es) | 2025-10-01 |
| CA3081456A1 (en) | 2019-05-09 |
| WO2019089884A2 (en) | 2019-05-09 |
| AU2018358250B2 (en) | 2025-06-05 |
| BR112020008478A2 (pt) | 2020-10-20 |
| JP2021502113A (ja) | 2021-01-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL274299A (en) | Methods, compositions and components for crispr-cas9 editing of tgfbr2 in t cells for immunotherapy | |
| IL282191A (en) | Methods and preparations for editing RN" A | |
| IL273817A (en) | Preparations and methods for editing rna | |
| IL287248A (en) | Methods and preparations for editing RN" A | |
| IL320642B1 (en) | Compositions and methods for t cell engineering | |
| IL282225B1 (en) | Immunotherapy preparations and methods | |
| IL263744A (en) | Compositions and methods for depleting cd117 plus cells | |
| IL274154A (en) | Compositions and methods for diluting CD117 plus cells | |
| IL263743A (en) | Compositions and methods for the depletion of cells | |
| SG11201912010XA (en) | Pde5 compositions and methods for immunotherapy | |
| EP3700540A4 (en) | COMPOSITIONS AND METHODS OF DEPRODUCTION FROM CD117 + CELLS | |
| EP3331582A4 (en) | METHODS AND COMPOSITIONS FOR THE TREATMENT OF TRANSPLANTATION CELLS | |
| IL268058A (en) | Compositions and methods for depleting CD137 plus cells | |
| EP3129471A4 (en) | Method and compositions for cellular immunotherapy | |
| SG10202107602XA (en) | Methods and compositions for gene editing in hematopoietic stem cells | |
| EP3230460A4 (en) | Methods and compositions for selectively eliminating cells of interest | |
| IL271232A (en) | Compounds and methods for editing the genome | |
| EP3212225A4 (en) | Methods and compositions for modified t cells | |
| MA39819A (fr) | Méthodes et compositions d'immunomodulation | |
| EP3242940A4 (en) | Methods and compositions for combination immunotherapy | |
| EP3286213A4 (en) | Methods and compositions for combination immunotherapy | |
| EP3247408A4 (en) | Compositions and methods for cancer immunotherapy | |
| EP3208614A4 (en) | Composition for diagnosing pancreatic cancer and method for diagnosing pancreatic cancer by using same | |
| WO2017107898A9 (en) | Compositions and methods for gene editing | |
| SG11202004192XA (en) | Compositions and methods for the depletion of cd2+ cells |